Multiple Myeloma | Specialty

Treating Myeloma: Newly Diagnosed Transplant-Eligible Patients

June 26th 2019

Clinical Trials' Impact on Smoldering Myeloma Management

June 26th 2019

Smoldering Myeloma: Treatment and Risk Stratification

June 26th 2019

FDA Lifts Partial Clinical Hold on Venetoclax Myeloma Trial

June 25th 2019

The FDA has lifted a partial clinical hold that was placed on the phase III CANOVA (M13-494; NCT03539744) trial, which is examining venetoclax in combination with pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma that harbors t(11;14), according to AbbVie, the company that co-develops the BCL-2 inhibitor with Roche.

Rapid Changes in Multiple Myeloma Provide a Windfall of Treatment Options

June 21st 2019

S. Vincent Rajkumar, MD, discusses the rapidly changing landscape for the treatment of multiple myeloma, the future of immunomodulatory drugs, and whether quadruplet regimens will become more frequent.

Dr. Rajkumar on Quadruplet Regimens in Multiple Myeloma Treatment

June 20th 2019

S. Vincent Rajkumar, a professor of Medicine at the Mayo Clinic, Rochester, Minnesota, discusses the prevalence of quadruplet regimens in treating patients with multiple myeloma.

Dr. Pecora on Updated MAIA Data in Multiple Myeloma

June 20th 2019

Andrew Pecora, MD, FACP, CPE, president physician enterprise, chief innovation officer, John Theurer Cancer Center, Hackensack Meridian Health, discusses the impact age has on the efficacy and safety of daratumumab in combination with lenalidomide and dexamethasone (DRd) in patients with transplant-ineligible newly diagnosed multiple myeloma (NDMM) as part of the MAIA study.

Phase III BELLINI Data Showcase Safety Concerns With Venetoclax in Multiple Myeloma

June 16th 2019

Despite promising progression-free survival and response data with venetoclax in combination with bortezomib and dexamethasone, an increased number of deaths due to infection in the experimental arm marred overall survival findings in patients with relapsed/refractory multiple myeloma.

Elotuzumab Triplet Continues to Show Survival Benefit in Relapsed/Refractory Myeloma

June 14th 2019

The triplet regimen of elotuzumab plus pomalidomide and dexamethasone led to a 46% reduction in the risk of death compared with pomalidomide/dexamethasone alone in patients with relapsed/refractory multiple myeloma, according to updated findings of the phase II ELOQUENT-3 trial.

Dr. Chari on the INSIGHT MM Study on Multiple Myeloma

June 14th 2019

Ajai Chari, MD, Icahn School of Medicine at Mount Sinai, discusses INSIGHT MM (NCT02761187), the largest global, prospective, non-interventional, observational study on multiple myeloma to date.

Innovation Fuels Survival Gains in Multiple Myeloma

June 12th 2019

While the expansion of therapeutic opportunity in multiple myeloma has been incremental in some ways, it’s been continuous and, when seen in aggregate, the impact is considerable.

Dr. Kang on the Preclinical Activity of ABC294640 in Multiple Myeloma

June 8th 2019

Yubin Kang, MD, a professor of medicine and member of Duke Cancer Institute, discusses the preclinical activity of the SK-2 inhibitor ABC294640 in multiple myeloma.

Novel Triplets, Potent Single Agents Emerge Across Myeloma Spectrum

June 7th 2019

Yubin Kang, MD, discusses how progress made in frontline therapy has impacted the outlook of multiple myeloma and the remaining work that needs to be done across settings.

Dr. Gasparetto on Therapies for Patients With Penta-Refractory Myeloma

June 5th 2019

Cristina Gasparetto, MD, an associate professor of medicine and director, Multiple Myeloma Program at Duke Cancer Institute, discusses therapies for patients with penta-refractory multiple myeloma.

Dr. Richardson on Isatuximab Triplet Regimen in Relapsed/Refractory Myeloma

June 4th 2019

Paul G. Richardson, MD, clinical program leader and director of clinical research at the Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute, discussed the phase III ICARIA-MM trial, which looked at the triplet regimen of isatuximab, pomalidomide (Pomalyst), and dexamethasone in patients with relapsed/refractory multiple myeloma.

Isatuximab Triplet Significantly Improves PFS in Myeloma

June 3rd 2019

Adding isatuximab to pomalidomide and low-dose dexamethasone led to a greater than 40% reduction in the risk of disease progression or death compared with pomalidomide and dexamethasone alone in patients with relapsed/refractory multiple myeloma.

Subcutaneous Daratumumab Shows Similar Efficacy, Greater Convenience in Phase III Myeloma Trial

June 3rd 2019

A subcutaneous flat-dose version of daratumumab demonstrated noninferior efficacy with a reduction in the treatment burden compared with the original intravenous formulation of the anti-CD38 monoclonal antibody for patients with relapsed/refractory multiple myeloma.

Alarm Sounded Over Multiple Myeloma Outcomes Versus Socioeconomics

June 2nd 2019

Higher income was associated with significantly greater probability of survival for patients with multiple myeloma, according to authors of a study they performed to call attention to the need to address socioeconomic disparities that influence treatment outcomes.

ASCO 2019: Dr. Plimack Highlights Practice-Changing Data for Genitourinary Cancers

June 2nd 2019

ASCO 2019: Dr. Ferris Discusses the Latest Data in Head and Neck Cancer

June 2nd 2019